Hiroshi Aikata

18.9k total citations
254 papers, 4.8k citations indexed

About

Hiroshi Aikata is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Hiroshi Aikata has authored 254 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Hepatology, 124 papers in Epidemiology and 59 papers in Surgery. Recurrent topics in Hiroshi Aikata's work include Liver Disease Diagnosis and Treatment (102 papers), Hepatocellular Carcinoma Treatment and Prognosis (101 papers) and Hepatitis C virus research (73 papers). Hiroshi Aikata is often cited by papers focused on Liver Disease Diagnosis and Treatment (102 papers), Hepatocellular Carcinoma Treatment and Prognosis (101 papers) and Hepatitis C virus research (73 papers). Hiroshi Aikata collaborates with scholars based in Japan, United States and Italy. Hiroshi Aikata's co-authors include Kazuaki Chayama, Michio Imamura, Yoshiiku Kawakami, Tomokazu Kawaoka, Shoichi Takahashi, Akira Hiramatsu, Masataka Tsuge, C. Nelson Hayes, Takashi Nakahara and Hidenori Ochi and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Hiroshi Aikata

241 papers receiving 4.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroshi Aikata Japan	37	3.3k	2.3k	1.1k	616	608	254	4.8k
Si Hyun Bae South Korea	40	3.9k 1.2×	2.7k 1.2×	1.1k 1.0×	536 0.9×	818 1.3×	250	5.6k
Sherrie Bhoori Italy	25	2.6k 0.8×	1.7k 0.7×	1.2k 1.1×	316 0.5×	694 1.1×	58	3.8k
Antonietta D’Errico Italy	36	1.7k 0.5×	1.4k 0.6×	1.3k 1.2×	306 0.5×	965 1.6×	180	4.2k
Won Young Tak South Korea	37	3.4k 1.0×	2.3k 1.0×	1.4k 1.3×	916 1.5×	901 1.5×	201	5.9k
Mercedes Iñarrairaegui Spain	32	5.0k 1.5×	3.0k 1.3×	1.4k 1.3×	563 0.9×	1.5k 2.5×	105	6.5k
Arndt Weinmann Germany	32	1.7k 0.5×	1.1k 0.5×	691 0.7×	383 0.6×	716 1.2×	161	3.3k
Diethelm Messinger Germany	25	3.3k 1.0×	4.0k 1.7×	1.6k 1.6×	360 0.6×	549 0.9×	93	7.2k
Gerd Otto Germany	40	2.7k 0.8×	1.8k 0.8×	1.7k 1.6×	338 0.5×	1.2k 2.0×	108	5.3k
Byung Chul Yoo South Korea	38	3.7k 1.1×	2.9k 1.3×	1.3k 1.3×	286 0.5×	537 0.9×	135	4.8k
Jeong Won Jang South Korea	35	3.1k 0.9×	2.3k 1.0×	656 0.6×	284 0.5×	851 1.4×	219	4.4k

Countries citing papers authored by Hiroshi Aikata

Since Specialization

Citations

This map shows the geographic impact of Hiroshi Aikata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Aikata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Aikata more than expected).

Fields of papers citing papers by Hiroshi Aikata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Aikata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Aikata. The network helps show where Hiroshi Aikata may publish in the future.

Co-authorship network of co-authors of Hiroshi Aikata

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Aikata. A scholar is included among the top collaborators of Hiroshi Aikata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Aikata. Hiroshi Aikata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kudo, Masatoshi, Masafumi Ikeda, Hiroshi Aikata, et al.. (2024). First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial. Liver Cancer. 14(4). 365–377.

Cheng, Jason Chia‐Hsien, Taek‐Keun Nam, Jin Hee Kim, et al.. (2023). Efficacy of Liver-Directed Combined Radiotherapy in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers. 15(12). 3164–3164. 6 indexed citations

Uchida, Takuro, Michio Imamura, C. Nelson Hayes, et al.. (2023). HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice. Hepatology. 78(3). 929–942. 7 indexed citations

Kato, Naoya, Masatoshi Kudo, Kaoru Tsuchiya, et al.. (2023). Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study. Hepatology Research. 53(5). 409–416. 3 indexed citations

Nakagawa, Hidewaki, Atsushi Ono, Hiroshi Aikata, et al.. (2022). Comprehensive analysis of full-length transcripts reveals novel splicing abnormalities and oncogenic transcripts in liver cancer. PLoS Genetics. 18(8). e1010342–e1010342. 15 indexed citations

Fujita, Masashi, Mei-Ju May Chen, Doris R. Siwak, et al.. (2022). Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nature Communications. 13(1). 6481–6481. 13 indexed citations

Hiraoka, Atsushi, Masato Nakai, Nagisa Hara, et al.. (2022). Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test. Hepatology Research. 53(1). 43–50. 3 indexed citations

Uchida, Takuro, Michio Imamura, Hiromi Abe‐Chayama, et al.. (2022). A novel cDNA‐uPA/SCID/Rag2^−/−/Jak3^−/− mouse model for hepatitis virus infection and reconstruction of human immune system. Journal of Viral Hepatitis. 30(3). 262–272. 1 indexed citations

Nakahara, Takashi, Masafumi Ono, Takumi Kawaguchi, et al.. (2021). Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. Journal of Gastroenterology and Hepatology. 37(3). 592–599. 5 indexed citations

10.

Uchikawa, Shinsuke, Tomokazu Kawaoka, Yuwa Ando, et al.. (2020). Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. Oncology. 98(10). 727–733. 7 indexed citations

11.

Takaki, Shintaro, Michio Imamura, Shuji Yamaguchi, et al.. (2020). Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clinical Journal of Gastroenterology. 13(6). 1233–1238. 3 indexed citations

12.

Tada, Toshifumi, Hidenori Toyoda, Takashi Kumada, et al.. (2020). Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. Journal of Viral Hepatitis. 28(3). 538–547. 2 indexed citations

13.

Kodama, Kenichiro, Tomokazu Kawaoka, Shinsuke Uchikawa, et al.. (2019). Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. Oncology. 97(2). 75–81. 32 indexed citations

14.

Fujino, Hatsue, Mio Tanaka, Michio Imamura, et al.. (2019). Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterology. 19(1). 169–169. 15 indexed citations

15.

Kudo, Masatoshi, Kazuomi Ueshima, Yasutaka Chiba, et al.. (2019). Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer. 8(6). 505–519. 12 indexed citations

16.

Uchikawa, Shinsuke, Tomokazu Kawaoka, Kenichiro Kodama, et al.. (2019). Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer. 9(2). 148–155. 29 indexed citations

17.

Ohya, Kazuki, Michio Imamura, Yuji Teraoka, et al.. (2019). Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. Clinical Journal of Gastroenterology. 13(2). 267–270. 3 indexed citations

18.

Nakano, Ryosuke, Masahiro Ohira, Tsuyoshi Kobayashi, et al.. (2018). Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity-matched analysis in a single institution. Surgery. 164(2). 219–226. 18 indexed citations

19.

Kawaoka, Tomokazu, Hiroshi Aikata, Yuji Teraoka, et al.. (2017). Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. Oncology. 92(6). 335–346. 11 indexed citations

20.

Tanimine, Naoki, Yuka Tanaka, Tsuyoshi Kobayashi, et al.. (2014). Quantitative Effect of Natural Killer–Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy. Cancer Immunology Research. 2(12). 1142–1147. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact